All
Derm In The News: April 28-May 4
Keep up with the latest headlines in dermatology from the past week, including the invention of a groundbreaking method for detecting skin cancer using Terahertz waves, a survey indicative of young people's perceptions of sun exposure, and more.
The Weekly Roundup: April 29-May 3
In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more.
Journal Digest: May 3
This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.
Alpha Tau to Conduct Trial of Alpha DaRT Technology In Patients With Recurrent Squamous Cell Carcinoma
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Recognizing Melanoma and Skin Cancer Awareness Month
Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.
QUIZ RECAP: Test Your Knowledge of Rosacea Research and Innovations
Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.
Reviewing Concerns For Mental Health and Well-Being in Dermatologic Conditions
May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.
JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases
A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
ASLAN Expands Collaboration with Zenyaku to Investigate Eblasakimab’s MOA Compared to Other Biologics in AD
The new research will compare eblasakimab to dupilumab and lebrikizumab.
Skin Cancer Breakthroughs, Prevention, and Treatment Advances During the Past Year
This recap of skin cancer innovations accompanies the cover story of our May publication.
Supporting Patients With AD and Their Caregivers: Insights from Argentina
A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.
Study Is First to Analyze Content and Influence of Fairness Cream Commercials From South Asia
While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.
Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
FDA Approves A High-Concentration, Citrate-Free Version of Cyltezo, A Biosimilar to Humira
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
Dermatology Conferences and Meetings Calendar 2024: May
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
3 Things You Should Know About HS Pathology and Management
Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.
Discovering Dermatology Times: April 2024
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
Rosacea Awareness Month Recap
Review Dermatology Times' coverage of Rosacea Awareness Month.
Dermatology Times April 2024 Recap
Dermatology Times is looking back on the top stories in dermatology from the month of April.
Eli Lilly Resubmits BLA for Lebrikizumab for the Treatment of Moderate to Severe AD
A decision from the FDA is expected in the second half of 2024.
Interview Intersection: Expert Interviews From April 2024
Dermatology Times is recapping our top expert interviews from the month of April.
Anna López-Ferrer, MD, PhD, and Volker Koscielny, MD, MBA, Share Highlights From Almirall’s 15th Skin Academy
López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.
Versus Red Light PDT, Patients With Actinic Keratosis Prefer Simulated Daylight PDT
A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.
Cosmetic, Psychological Impact of Punch Biopsy in Patients With Tattooed Skin is Minimal
A study found that in addition, recovery time was both quick and yielded minimal symptoms.
FDA Accepts Dermavant’s sNDA for Tapinarof Cream 1% for Adults and Children With AD
The FDA’s PDUFA date is expected in quarter 4 of 2024.
QUIZ: Test Your Knowledge of Rosacea Research and Innovations
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.
Derm In The News: April 21-27
Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.
The Weekly Roundup: April 22-26
ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union's approval of bimekizumab for HS, and more.
Clinician and Patient Perspective: Tapinarof Cream for Plaque Psoriasis
Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.
Optical Coherence Tomography in Preoperative Mapping of BCC: A Novel Approach to Optimizing Mohs Micrographic Surgery
Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.